(2R)-2,4-Dimethyl-1-piperazinecarboxylic Acid 4-[(3-chloro-2-fluorophenyl)amino]-7-metho-xy-6-CAS 1626387-80-1

Product Description:
(2R)-2,4-Dimethyl-1-piperazinecarboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-metho-xy-6-quinazolinyl ester CAS 1626387-80-1

Synonyms:

AZD3759;4-[(3-Chloro-2-fluorophenyl)amino]-7-metho-xy-6-quinazolinyl (2R)-2,4-dimethyl-1-piperazinecarboxylate;4-((3-chloro-2-fluorophenyl)amino)-7-metho-xyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate

Chemical & Physical Properties

Appearance:solid

Density:1.4±0.1 g/cm3

Boiling Point:571.4±50.0℃at 760 mmHg

Melting Point:192.4℃(alcohol,ester), 193.3℃ (water)

Molecular Formula:PC22H23ClFN5O3

Molecular Weight:459.901

Flash Point:299.3±30.1℃

Exact Mass:459.147339

PSA :79.82000

LogP:4.92

Vapour Pressure:0.0±1.6 mmHg at 25℃

Index of Refraction:1.632

Uses :

AZD3759 is another extremely effective drug with 100% intracranial permeability and far more effective than Erlotinib, Gefitinib, Afatinib and oxitinib. Non small cell lung cancer patients with brain metastasis will have neurological dysfunction: unresponsiveness, dementia, Seizure, dyskinesia, etc. Accompanied by a significant decrease in quality of life, extremely poor prognosis, and a lack of very effective treatment methods. One of the reasons is the existence of the "Blood–brain barrier", which can prevent harmful substances in the blood from seeping into the brain tissue through the Chemicalbook, and also limit the drugs from reaching the brain tissue; The second reason is that it is not sensitive to some anti-tumor drugs that can penetrate into brain tissue. Therefore, surgery and radiation therapy have been the main treatment methods for brain metastases in the past. Radiation therapy can effectively control the progression of brain metastases, but its effect on prolonging survival time is limited. In recent years, the rapid development of molecular targeting, anti angiogenesis therapy, Immunosuppressive drug and other drugs has provided more treatment methods for brain metastasis of lung cancer and improved the survival of such patients.

It is applicable to the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with Epidermal growth factor receptor (EGFR) mutation positive and central nervous system (CNS) metastasis.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.